Journal of International Oncology››2021,Vol. 48››Issue (12): 705-710.doi:10.3760/cma.j.cn371439-20210813-00140
• Original Articles •Next Articles
Zhao Lili1, Zhao Wenwen2, Feng Qingqing2, Zhao Wenfei2, Zhang Xue1, Jing Wenjun2, Wei Hongmei2
Received:
2021-08-13Revised:
2021-10-03Online:
2021-12-08Published:
2022-01-12Zhao Lili, Zhao Wenwen, Feng Qingqing, Zhao Wenfei, Zhang Xue, Jing Wenjun, Wei Hongmei. Effects of silencing PD-L1 expression on biological behaviors of gastric cancer cells[J]. Journal of International Oncology, 2021, 48(12): 705-710.
"
基因名称 | 引物序列 |
---|---|
PD-L1 | 正向引物:5'-AGACCACCACCACCAATTCC-3' |
反向引物:5'-ACGGAAGATGAATGTCAGTGC-3' | |
上皮钙黏素 | 正向引物:5'-TCACATCCTACACTGCCCAG-3' |
反向引物:5'-AGTGTCCCTGTTCCAGTAGC-3' | |
波形蛋白 | 正向引物:5'-TTGAACGCAAAGTGGAATC-3' |
反向引物:5'-AGGTCAGGCTTGGAAACA-3' | |
Snail | 正向引物:5'-CCCCAATCGGAAGCCTAACT-3' |
反向引物:5'-GACAGAGTCCCAGATGAGCA-3' | |
GAPDH | 正向引物:5'-TCAAGAAGGTGGTGAAGCAGG-3' |
反向引物:5'-TCAAAGGTGGAGGAGTGGGT-3' |
[1] | Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3):209-249. DOI: 10.3322/caac.21660. |
[2] | Farran B, Müller S, Montenegro RC. Gastric cancer managment: kinases as a target therapy[J]. Clin Exp Pharmacol Physiol, 2017,44(6):613-622. DOI: 10.1111/1440-1681.12743. |
[3] | Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial[J]. JAMA Oncol, 2018, 4(5): e180013. DOI 10.1001/jamaoncol.2018.0013. |
[4] | Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): arandomised, double-blind, placebo-controlled, phase 3trial[J]. Lancet, 2017,390(10111):2461-2471. DOI: 10.1016/S0140-6736(17)31827-5. |
[5] | Böger C, Behrens HM, Mathiak M, et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients[J]. Oncotarget, 2016,7(17):24269-24283. DOI: 10.18632/oncotarget.8169. |
[6] | Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape[J]. Sci Transl Med, 2012, 4(127): 127ra37. DOI: 10.1126/scitranslmed.3003689. |
[7] | Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance[J]. Cell, 2008,133(5):775-787. DOI: 10.1016/j.cell.2008.05.009. |
[8] | Ghebeh H, Tulbah A, Mohammed S, et al. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells[J]. Int J Cancer, 2007,121(4):751-758. DOI: 10.1002/ijc.22703.7. |
[9] | Shi SJ, Wang LJ, Wang GD, et al. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells[J]. PLoS One, 2013,8(10):e76012. DOI: 10.1371/journal.pone.0076012. |
[10] | Liu M, Wang R, Sun X, et al. Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients[J]. Mol Oncol, 2020,14(4):865-881. DOI: 10.1002/1878-0261.12643. |
[11] | 龙琼先, 彭勇, 唐治蓉 , 等. 卵巢癌组织中PD-L1表达与EMT及其转录因子的相关性[J]. 现代肿瘤医学, 2020,28(18):3214-3218. DOI: 10.3969/j.issn.1672-4992.2020.18.026. |
[12] | Chen L, Xiong Y, Li J, et al. PD-L1 expression promotes epithelial to mesenchymal transition in human esophageal cancer[J]. Cell Physiol Biochem, 2017,42(6):2267-2280. DOI: 10.1159/000480000. |
[13] | Eichberger J, Schulz D, Pscheidl K, et al. PD-L1 influences cell spreading, migration and invasion in head and neck cancer cells[J]. Int J Mol Sci, 2020,21(21):8089. DOI: 10.3390/ijms21218089. |
[1] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[2] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[3] | Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165. |
[4] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[5] | Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong.Effects of Anhydroicaritin on the proliferation, migration and apoptosis of hepatocellular carcinoma cells[J]. Journal of International Oncology, 2023, 50(9): 513-519. |
[6] | Shao Huifang, Wang Xuehong, Lu Yongfu.Mechanism of action and clinical significance of CST1 in the progression of gastric cancer[J]. Journal of International Oncology, 2023, 50(8): 489-492. |
[7] | Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu.Level of serum FABP1 and its relationship withHelicobacter pyloriinfection in patients with gastric cancer[J]. Journal of International Oncology, 2023, 50(6): 336-341. |
[8] | Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207. |
[9] | Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen.Correlation between blood lipid level and gastric cancer[J]. Journal of International Oncology, 2023, 50(3): 183-185. |
[10] | Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen.Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 112-116. |
[11] | Yang Jun, Li Rong, Zeng Jianchang.Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 82-86. |
[12] | Deng Lili, Duan Xingyu, Li Baozhong.Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma[J]. Journal of International Oncology, 2023, 50(12): 751-757. |
[13] | Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan.Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer[J]. Journal of International Oncology, 2023, 50(11): 677-682. |
[14] | Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei.Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(10): 631-635. |
[15] | Wang Yue, Hu Qun, Hou Yingwei.Research progress in influences of epigenetic modifications on PD-L1 expression in tumors[J]. Journal of International Oncology, 2022, 49(6): 345-348. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||